Comparative Pharmacology
Head-to-head clinical analysis: FERTINEX versus REPRONEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FERTINEX versus REPRONEX.
FERTINEX vs REPRONEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Follitropin beta, a recombinant form of human follicle-stimulating hormone (FSH), binds to the FSH receptor on ovarian granulosa cells and testicular Sertoli cells, stimulating follicular development and maturation in women and spermatogenesis in men.
REPRONEX (urofollitropin) is a purified preparation of follicle-stimulating hormone (FSH) that stimulates ovarian follicular growth in women who do not have primary ovarian failure. It acts by binding to FSH receptors on granulosa cells, increasing cAMP and promoting follicular development and estrogen synthesis.
For ovulation induction: 75-150 IU subcutaneously or intramuscularly once daily for 7-12 days; for spermatogenesis: 75-150 IU subcutaneously or intramuscularly 3 times per week.
Men: 1000-2500 IU subcutaneously 3 times weekly for 6-12 months. Women: 75-300 IU subcutaneously or intramuscularly daily for 7-12 days.
None Documented
None Documented
Terminal elimination half-life is approximately 24-36 hours in patients with normal renal function, supporting once-daily dosing.
Terminal elimination half-life: 24-30 hours (menotropins); clinically, it supports daily dosing during ovarian stimulation
Primarily renal excretion of unchanged drug (80-90% of administered dose), with the remainder excreted as metabolites in urine and feces.
Renal (approximately 80% as parent drug and metabolites); biliary/fecal (<5%)
Category C
Category C
Gonadotropin
Gonadotropin